Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, gives updates on the first-in-human phase I study of TTI-621 in patients with relapsed/refractory hematologic malignancies. TTI-621 (SIRPαFc) is a novel biologic that targets CD47 and shows promising anti-tumor activity. Dosing was initially difficult to ascertain as platelets also contain these signals and were depleted as a result. However, dosing has since been clarified and the results presented at ASH 2020. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.